
Moffitt Researchers Show That Reactivity to Tumor Antigens is Important for TIL Therapy
Newswise — TAMPA, Fla. (May 8, 2025) — A team of researchers from Moffitt Cancer Center has found new insight into why some lung cancer patients do not benefit from tumor-infiltrating lymphocyte, or TIL therapy. Their findings, published in Nature Cancer, …